Ieq Capital LLC Takes Position in REGENXBIO Inc. $RGNX

Key Points

• Ieq Capital LLC has acquired 50,969 shares of REGENXBIO Inc., valued at approximately $364,000, representing about 0.10% ownership of the company.
• Recent analyst reports have seen varied ratings and price targets for REGENXBIO, with Barclays setting a new target of $37.00 while Chardan Capital maintains a buy rating with a target of $52.00.
• REGENXBIO reported a loss of ($1.38) EPS in its latest quarterly earnings, missing estimates and raising concerns about its current revenue stream compared to expectations.

Ieq Capital LLC purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 50,969 shares of the biotechnology company's stock, valued at approximately $364,000. Ieq Capital LLC owned 0.10% of REGENXBIO as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in RGNX. 22NW LP acquired a new position in shares of REGENXBIO in the first quarter valued at approximately $4,781,000. Pale Fire Capital SE grew its holdings in shares of REGENXBIO by 120.5% in the first quarter. Pale Fire Capital SE now owns 25,846 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 14,125 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of REGENXBIO by 657.7% in the first quarter. AlphaQuest LLC now owns 60,309 shares of the biotechnology company's stock valued at $431,000 after purchasing an additional 52,350 shares in the last quarter. Voss Capital LP grew its holdings in shares of REGENXBIO by 17.2% in the first quarter. Voss Capital LP now owns 390,000 shares of the biotechnology company's stock valued at $2,788,000 after purchasing an additional 57,186 shares in the last quarter. Finally, Brooklyn Investment Group grew its holdings in shares of REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Stock Down 0.8%

NASDAQ RGNX traded down $0.08 on Thursday, hitting $9.49. 371,089 shares of the stock were exchanged, compared to its average volume of 571,030. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $13.48. The company has a market cap of $479.34 million, a PE ratio of -2.76 and a beta of 1.17. The company has a 50-day moving average price of $8.74 and a 200-day moving average price of $8.24.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The firm had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. As a group, equities research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGNX has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a report on Monday. Royal Bank Of Canada dropped their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Chardan Capital restated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Monday. Barclays dropped their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a report on Friday, August 8th. Finally, Wall Street Zen cut shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.